Joseph Benevento, MD
Retina Specialist · New Orleans, LANPI 1093840944
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,636 of the $4,380 with a category attached, or 60.2%. 12 manufacturers reported payments, led by Alimera Sciences, Inc. at 44.0% of the total. Reporting peaked in 2021 at $1,665 and has fallen 96.6% since, to $56 in 2025.
Across 30 payments — averaging $146.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$2K
- Alcon$627
- Regeneron Healthcare Solutions, Inc.$499
- Apellis Pharmaceuticals, Inc.$496
- Regeneron$269
- Astellas Pharma US Inc$146
- plus $417 from 6 others
Across 13 payments — averaging $2920.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$38K
What the payments were for
- Speaking & faculty fees$1,20027%
- Travel & lodging$54412%
- Food & beverage$2,63660%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 7 | $1,927 |
| Alcon | 4 | $627 |
| Regeneron Healthcare Solutions, Inc. | 4 | $499 |
| Apellis Pharmaceuticals, Inc. | 5 | $496 |
| Regeneron | 2 | $269 |
| Astellas Pharma US Inc | 2 | $146 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| Astellas Pharma Global Development | 1 | $113 |
| Eyepoint US, Inc. | 1 | $107 |
| Genentech USA, Inc. | 1 | $26 |
| Oyster Point Pharma, Inc. | 1 | $24 |
| AbbVie | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,380 in reported general payments places this provider in the 65th percentile of 30 retina specialist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 43 | $41,316 |
| Prednisolone Acetate | 116 | $6,760 |
| IlevroNepafenac | 16 | $6,157 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $5,853 |
| Ketorolac Tromethamine | 64 | $2,108 |
| Atropine Sulfate | 16 | $1,089 |
| Latanoprost | 107 | $1,065 |
| Timolol Maleate | 71 | $613 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 59 | $449 |
| ErythromycinErythromycin Base | 30 | $375 |
| Brimonidine Tartrate | 40 | $340 |
| Dorzolamide Hcl | 36 | $247 |
| Prednisone | 20 | $224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $21 | $47,17055 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 30 retina specialist providers in Louisiana.
Other retina specialist in New Orleans
- Donald MazzullaNew Orleans$215K
- Sidharth PuriNew Orleans$32K
- Gwen CousinsMetairie$10K
- Frank CulottaLafayette$9K
- Adam JanotBaton Rouge$8K
- Daniel SalisburyBaton Rouge$7K
- Scott GauthreauxLafayette$7K
- Brett BuddenMetairie$6K
- Arley Jaramillo RodriguezMetairie$6K
- Neil NotarobertoMetairie$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.